Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

[1]  K. Pradhan,et al.  Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.

[2]  N. Moskovits,et al.  Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer , 2021, JAMA oncology.

[3]  P. Maingon,et al.  Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients , 2021, Annals of Oncology.

[4]  E. Chamorey,et al.  Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors , 2021, Annals of Oncology.

[5]  M. Malim,et al.  Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.

[6]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[7]  M. Kaiser,et al.  Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma , 2021, The Lancet Haematology.

[8]  M. Dimopoulos,et al.  Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.

[9]  G. Shefer,et al.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia , 2021, Blood.

[10]  J. Warner,et al.  Care without a compass: Including patients with cancer in COVID-19 studies , 2021, Cancer Cell.

[11]  A. Wells,et al.  Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients , 2021, medRxiv.

[12]  J. Warner,et al.  Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium , 2021, Annals of Oncology.

[13]  V. Gushchin,et al.  Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.

[14]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[15]  K. Pradhan,et al.  Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy , 2020 .

[16]  N. Berger,et al.  Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. , 2020, JAMA oncology.

[17]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[18]  T. Choueiri,et al.  Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study , 2020, Cancer Cell.

[19]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[20]  J. Warner,et al.  COVID-19 and Cancer: Current Challenges and Perspectives , 2020, Cancer Cell.

[21]  M. Loda,et al.  SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19 , 2020, Cancer Cell.

[22]  A. Manenti,et al.  Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples , 2020, bioRxiv.

[23]  A. Tanuri,et al.  AN AFFORDABLE ANTI-SARS-COV-2 SPIKE ELISA TEST FOR EARLY DETECTION OF IgG SEROCONVERSION SUITED FOR LARGE-SCALE SURVEILLANCE STUDIES IN LOW-INCOME COUNTRIES , 2020, medRxiv.

[24]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[25]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[26]  Ping Li,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[27]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .